Dangerous Drugs and Pharmacogenomics on the Horizon
What’s it all about? Although the opioid epidemic is far from over, there is a growing concern that something far worse is on the horizon. Ironically, the use of opioids has spawned the use of other dangerous prescription drugs among injured workers. These include benzodiazepines, sedative sleep hypnotics, and even stimulants such as amphetamine. Will a decline in opioid use result in declining use of these other drugs, or will it create a separate problematic addiction? This is one of many questions to be covered in this session with Phil Walls, RpH from myMatrixx. There will be discussion of clinical pharmacy strategies to mitigate the risk from these other drugs, including an introduction to the emerging discipline of pharmacogenomics. Pharmacogenomics is the combination of pharmacology and genetics and holds promise to provide important information about how individual patients will react to drugs before they are prescribed. Finally, the medical marijuana/opioid connection will be critically examined to see if it has actually helped with the current crisis or whether it is introducing new risks!
Why you’ll want to participate in this session.
- Understand the Controlled Substance Act and the variety of dangerous drugs included in this act other than opioids, and discover the most prevalent dangerous drugs to which injured workers may be exposed.
- Gain knowledge of the concept of “risk versus benefit” when applied to drug selection by a prescriber. As an example, we will evaluate medical marijuana on that risk versus benefit continuum.
- Hear about the emerging field of pharmacogenomics.
Approved for 1.25 SHRM, HRCI (HR) General, and Maine Attorney CLE Credits.
Applying for CCMC Credit.